MedPage Today on MSN1d
MIND Diet and Cognitive Decline; Gene Therapy for Parkinson's; Curbing MS FatigueA high dose of the investigational gene therapy AAV-GAD, which delivers the glutamic acid decarboxylase ( GAD) gene to the ...
The incubator is designed to draw cell and gene therapy researchers and drugmakers to work at the hub, where they can develop ...
A Phase I/II trial (NCT05603312) with MeiraGTx's AAV-GAD Parkinson’s disease gene therapy has met its primary endpoint. The sham-controlled bridging study evaluated the company's AAV-GAD therapy ...
Armed with data from a small phase 1/2 bridging study, MeiraGTx is preparing to take its gene therapy for Parkinson's disease into a pivotal trial. Shares in the Anglo-US biotech rose sharply ...
Two oral presentations and nine poster presentations will highlight exciting progress in AskBio’s clinical and pre-clinical ...
News Medical on MSN20h
Human midbrain organoids: A promising tool in the fight against Parkinson's diseaseAdvancements in organoid technology are crucial for Parkinson's disease research, providing human-relevant models for ...
AbbVie has finally claimed FDA approval for its advanced Parkinson's disease therapy Vyalev, 18 months after the US regulator ...
allowing certain patients with anti-AAV antibodies to still be candidates for CNS-directed gene therapy. "In particular, an AAV2-GAD therapy in Parkinson's disease patients demonstrated that ...
The Michael J. Fox Foundation (MJFF) has launched a major new initiative to rapidly expedite development of therapeutic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback